Recent ADHD Drug Approvals: Efficacy, Side Effects, and When to Switch

A psychiatrist reviews four recently approved ADHD drugs, noting that the newest, centanafadine, has a smaller effect but causes less insomnia. Another option, viloxazine, works faster than older non-stimulants. The author advises that patients doing well on their current medication have little reason to change.

Centanafadine's selective norepinephrine action represents a deliberate pharmacological shift, aiming to preserve therapeutic benefit while reducing dopamine-related risks like euphoria and misuse potential. However, trial data shows its effectiveness is notably weaker than traditional amphetamines, making it a targeted option for specific patient populations rather than a universal replacement.

Qelbree's faster onset—one to two weeks versus four to eight for Strattera—addresses a common frustration with non-stimulant therapy. The caffeine interaction is a practical consideration for younger patients. Meanwhile, generic lisdexamfetamine's market entry may have the broadest real-world impact, though inconsistent supply across strengths tempers its immediate accessibility.